SCHEMBL26316675

SCHEMBL26316675

Cc1ccc(/C=C/c2ccc(COc3ccc(CCCCn4ccnn4)cc3)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 1/20 0.58
MINK1 Q8N4C8 1/20 0.58
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
HPGD P15428 1/20 0.40
HRH3 Q9Y5N1 2/20 0.37
ATP4A P20648 1/20 0.37
ATP4B P51164 1/20 0.37
HMOX1 P09601 1/20 0.37
MAOB P27338 1/20 0.36
PARP10 Q53GL7 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN11 Q06124 1/20 0.36
PPARG P37231 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26316671 0.91 ERBB2 (0.53) ERBB2MINK1NPC1RAB9ASMN1; SMN2
SCHEMBL22398050 0.86 ERBB2 (0.76) ERBB2MINK1HRH3HMOX1MAOB
SCHEMBL28478241 0.86 ERBB2 (0.76) ERBB2MINK1HRH3HMOX1MAOB
SCHEMBL3668068 0.86 ERBB2 (0.80) ERBB2MINK1NPC1RAB9ASMN1; SMN2
SCHEMBL3668064 0.86 ERBB2 (0.80) ERBB2MINK1NPC1RAB9ASMN1; SMN2
SCHEMBL28477880 0.85 ERBB2 (0.54) ERBB2MINK1NPC1RAB9ASMN1; SMN2
SCHEMBL26316661 0.83 ERBB2 (0.76) ERBB2MINK1NPC1RAB9ASMN1; SMN2
SCHEMBL6582554 0.83 HMOX1 (0.53) ERBB2MINK1NPC1RAB9ASMN1; SMN2
SCHEMBL26316726 0.82 RAB9A (0.46) ERBB2MINK1NPC1RAB9ASMN1; SMN2
SCHEMBL26316556 0.82 HRH1 (0.47) ERBB2MINK1NPC1RAB9AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2023-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, IDH1 ERBB2 2558/4885MINK1 1781/4885NPC1 3392/4885
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, NUTF2 ERBB2 2443/4885MINK1 1986/4885NPC1 3909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.